A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Apr 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called VX-670 for people with Myotonic Dystrophy Type I (DM1), a condition that affects muscle function. The main goals of the study are to find out how safe the treatment is over a long period, how well it works, and how the body processes the medication.

To participate in this trial, individuals must be between the ages of 65 and 74 and have already completed a previous study involving VX-670. The trial is currently not recruiting participants, but once it starts, eligible participants can expect close monitoring and support as they receive the treatment. It's important to note that certain health issues may prevent someone from joining the study, so specific guidelines will be followed to ensure the safety of all participants.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • • Completed study drug treatment in parent study VX23-670-001 (NCT06185764)
• Key Exclusion Criteria:
• • • History of any illness or any clinical condition as pre-specified in the protocol
• • Other protocol defined Inclusion/Exclusion criteria may apply.